Haemonetics HAE Blood Center — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Haemonetics's blood center — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Haemonetics's blood center — R&D?
- Haemonetics (HAE) reported blood center — R&D of $1.03M in Q1 2026.
- How has Haemonetics's blood center — R&D changed year-over-year?
- Haemonetics's blood center — R&D decreased by 26.3% year-over-year, from $1.4M to $1.03M.
- What is the long-term trend for Haemonetics's blood center — R&D?
- Over 3 years (2023 to 2026), Haemonetics's blood center — R&D has grown at a 0.9% compound annual growth rate (CAGR), from $4.37M to $4.49M.
- What does blood center — R&D mean?
- Captures the investment in innovation, product improvement, and new technology development specifically for the Blood Center business unit. This spending is critical for maintaining long-term competitiveness and addressing evolving clinical needs in blood collection. It serves as a leading indicator of the company's commitment to future product pipeline growth.